Literature DB >> 31184016

[A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue].

Kh S Ibishev1, P A Krainy1, V V Mitusov1, D V Sizyakin1, G A Magomedov1.   

Abstract

INTRODUCTION: Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate gland in the elderly.
MATERIALS AND METHODS: The results of an open, randomized comparative study of the effectiveness of Serenoa repens in the combination with Urtica dioiccus (Prostagut-forte) are presented in the article. All patients were divided into two groups, depending on the therapy. In group I (n=51) Serenoa repens in combination with Urtica dioiccus 160/120 mg twice daily for 3 months was given, while in Group II (n=51) patients were prescribed to Serenoa repens 320 mg once a day, for 3 months.
RESULTS: According to the results, herbal preparations, like Serenoa repens, are effective for the medical treatment of BPH, which is confirmed by a decrease in LUTS severity, an increase in Qmax, a decrease in postvoid residual urine volume and an intensity of the inflammatory process in the prostatic tissue. However, in patients with BPH associated with chronic inflammation, it is preferable to use Serenoa repens in combination with Urtica dioiccus.

Entities:  

Keywords:  Serenoa repens; benign prostatic hyperplasia; chronic bacterial prostatitis

Mesh:

Substances:

Year:  2019        PMID: 31184016

Source DB:  PubMed          Journal:  Urologiia        ISSN: 1728-2985


  1 in total

1.  Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH).

Authors:  Miriam Saponaro; Isabella Giacomini; Giulia Morandin; Veronica Cocetta; Eugenio Ragazzi; Genny Orso; Ilaria Carnevali; Massimiliano Berretta; Mariangela Mancini; Francesco Pagano; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.